Latest

09.09.2021

Why Atea Could Be the Frontrunner in the Covid Antiviral Race

Read Article
08.24.2021

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and O

Read Article
06.30.2021

Roche and Atea's small, early data peek sees experimental COVID drug slash viral load in hospital patients

Read Article
06.02.2021

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients

Read Article
03.31.2021

OncoResponse Raises $40.6 Million Series C Financing

Read Article
02.15.2021

Targeting a Key Marker of Clotting and Inflammation in COVID-19 Patients

Read Article
11.24.2020

Targeting Calcium Overload Could Improve Stroke Outcomes

Read Article
10.29.2020

COVID-19 viral biotech Atea Pharmaceuticals prices upsized IPO at $24 high end

Read Article
Up NextAbout Us